ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China · Delayed Price · Currency is CNY 9.52
+0.41 (4.50%)
At close: Aug 4, 2026
ChemPartner PharmaTech Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 1,140 | 1,135 | 970.2 | 1,138 | 1,327 | 1,691 |
Revenue Growth | 14.37% | 16.96% | -14.77% | -14.19% | -21.54% | 14.11% |
Gross Profit Gross Profit Growth | 314.06 | 326.7 | 202.6 | 279 | 327.04 | 532.22 |
Operating Income Operating Income Growth | -6.45 | 9.62 | -97.26 | -65.57 | -95.56 | 65.31 |
Net Income Net Income Growth | -11.39 | 13.41 | -226.47 | -916.75 | 378.59 | -402.25 |
Earnings Per Share EPS Growth | -0.03 | 0.03 | -0.45 | -1.84 | 0.76 | -0.81 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Offset of Business Segment Offset of Business Segment Growth | -16.73 |
Pharmaceutical R & D Services and Production Outsourcing Pharmaceutical R & D Services and Production Outsourcing Growth | 1,137 |
Headquarters and Funds Headquarters and Funds Growth | 5.39 |
Microecological Products and Services Microecological Products and Services Growth | 8.98 |
Total Total Growth | 1,135 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 464.68 | 457.39 | 369.37 | 349.47 | 761.66 | 179.44 |
Total Debt Total Debt Growth | 451.1 | 472.04 | 513.31 | 635.34 | 966.2 | 1,747 |
Net Cash (Debt) Net Cash Growth | 13.58 | -14.65 | -143.93 | -285.88 | -204.53 | -1,568 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 0.03 | -0.03 | -0.29 | -0.57 | -0.41 | -3.16 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 221.72 | 190.5 | 168.21 | 150.99 | 262.46 | 378.22 |
Capital Expenditures CapEx Growth | -68.06 | -62.47 | -69.25 | -201.29 | -336.2 | -286 |
Free Cash Flow Free Cash Flow Growth | 153.66 | 128.03 | 98.96 | -50.3 | -73.74 | 92.22 |
Free Cash Flow Growth | 41.06% | 29.37% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 27.54% | 28.79% | 20.88% | 24.51% | 24.65% | 31.48% |
Operating Margin | -0.57% | 0.85% | -10.03% | -5.76% | -7.20% | 3.86% |
Pretax Margin | -1.47% | 1.41% | -23.88% | -82.55% | 56.14% | -21.35% |
Profit Margin | -1.00% | 1.18% | -23.34% | -80.53% | 28.54% | -23.79% |
FCF Margin | 13.48% | 11.28% | 10.20% | -4.42% | -5.56% | 5.46% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | 354.94 | - | - | 13.69 | - |
Forward PE | - | 21.25 | 21.25 | 21.25 | 21.25 | 21.25 |
P/FCF Ratio | 29.52 | 37.18 | 32.19 | - | - | 74.63 |
PS Ratio | 3.98 | 4.20 | 3.28 | 3.35 | 3.91 | 4.07 |